Form 4: Adaptimmune Therapeutics Director Acquires Options to Purchase Over 1 Million Ordinary Shares

Garry E. Menzel, a director of Adaptimmune Therapeutics PLC, reported acquiring options to purchase 1,121,604 ordinary shares on July 1, 2024.

Summary

• On July 1, 2024, Garry E. Menzel, a director of Adaptimmune Therapeutics PLC, acquired options to purchase 1,121,604 ordinary shares.
• The exercise price of these options is $0.16 per share, converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00.
• The options are exercisable from July 1, 2025, and expire on July 1, 2034.
• Following the transaction, Mr. Menzel directly owns 1,121,604 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a director acquiring options. While insider buying can be seen as positive, it's not necessarily a strong indicator of future performance.

Positives

• A director's acquisition of options may signal confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates